• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乌干达西南部使用 dapivirine 阴道环后风险补偿的评估。

Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.

机构信息

Department of HIV Interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda

Department of Statistics, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.

出版信息

Sex Transm Infect. 2022 Feb;98(1):32-37. doi: 10.1136/sextrans-2020-054718. Epub 2021 Feb 4.

DOI:10.1136/sextrans-2020-054718
PMID:33542153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8785055/
Abstract

OBJECTIVES

Participation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.

METHODS

We used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at baseline and quarterly for 2 years. Risk compensation was defined as a significant increase (trend p<0.05) in the proportion of women reporting risky sexual behaviour or a diagnosed STI between baseline and end of follow-up.

RESULTS

Between September 2013 and December 2016, 197 women (active arm: n=132 and placebo: n=65) were enrolled at the Masaka site. There were decreases in all markers of sexual risk behaviour with statistically significant decreases in only the proportion of women reporting ≥2 sexual partners, p=0.026 and those diagnosed with p<0.001 and or p<0.001 CONCLUSIONS: No evidence of risk compensation was observed in this trial.

TRIAL REGISTRATION NUMBER

NCT01539226.

摘要

目的

参与艾滋病毒预防试验可能会引发参与者的风险补偿。我们评估了乌干达西南部一项 III 期试验中女性使用阴道环杀微生物剂后的潜在风险补偿。

方法

我们使用标准问卷记录的性风险行为标志物，在基线和 2 年内每季度进行一次性传播感染检测。风险补偿定义为报告性行为风险或诊断性传播感染的女性比例在基线和随访结束之间显著增加（趋势 p<0.05）。

结果

2013 年 9 月至 2016 年 12 月，在马萨卡地点招募了 197 名女性（实验组：n=132 名和安慰剂组：n=65 名）。所有性风险行为标志物均呈下降趋势，仅报告≥2 个性伴侣的女性比例和诊断为的女性比例具有统计学显著下降，分别为 p=0.026 和 p<0.001 和或 p<0.001。

结论

在这项试验中未观察到风险补偿的证据。

试验注册号

NCT01539226。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4f/8785055/3b5796328ee6/sextrans-2020-054718f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4f/8785055/3b5796328ee6/sextrans-2020-054718f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4f/8785055/3b5796328ee6/sextrans-2020-054718f01.jpg

相似文献

1
Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.乌干达西南部使用 dapivirine 阴道环后风险补偿的评估。
Sex Transm Infect. 2022 Feb;98(1):32-37. doi: 10.1136/sextrans-2020-054718. Epub 2021 Feb 4.
2
Associations between intravaginal practices and incidence of sexually transmitted infections and bacterial vaginosis among women enrolled in the dapivirine vaginal ring trial (The Ring Study) in southwestern Uganda: a retrospective secondary analysis.在乌干达西南部参加地蒽诺素阴道环试验（环研究）的女性中，阴道内操作与性传播感染和细菌性阴道病发病率之间的关联：回顾性二次分析。
BMJ Open. 2024 Apr 8;14(4):e079497. doi: 10.1136/bmjopen-2023-079497.
3
Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.在 Microbicide Trials Network-020 三期临床试验中，接受地蒽诺辛阴道环治疗的血清转换者开始抗逆转录病毒治疗的临床和病毒学结局。
Clin Infect Dis. 2019 Jul 18;69(3):523-529. doi: 10.1093/cid/ciy909.
4
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.安全性、接受度和使用 dapivirine 阴道环预防非洲妇女感染 HIV-1（HOPE）：一项开放标签扩展研究。
Lancet HIV. 2021 Feb;8(2):e87-e95. doi: 10.1016/S2352-3018(20)30304-0.
5
Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.在一项艾滋病毒预防临床试验中，地蒽酚阴道环对女性性体验和亲密伴侣关系的影响：管理环检测和激情性爱。
AIDS Behav. 2018 Feb;22(2):437-446. doi: 10.1007/s10461-017-1977-1.
6
Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.男性伴侣参与对女性在 III 期 HIV 预防试验中对双夫定阴道环的依从性的影响。
AIDS Behav. 2020 May;24(5):1432-1442. doi: 10.1007/s10461-019-02707-1.
7
Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.从 dapivirine 阴道环中释放出更多的 dapivirine 与降低 HIV-1 感染风险相关：一项随机、安慰剂对照试验的二次分析。
J Int AIDS Soc. 2020 Nov;23(11):e25634. doi: 10.1002/jia2.25634.
8
Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe.马拉维、南非、乌干达和津巴布韦的男性使用 dapivirine 阴道环的性经历。
AIDS Behav. 2021 Jun;25(6):1890-1900. doi: 10.1007/s10461-020-03119-2. Epub 2021 Jan 2.
9
Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.参与达匹韦林阴道环预防HIV-1随机临床试验的女性特征。
PLoS One. 2015 Jun 10;10(6):e0128857. doi: 10.1371/journal.pone.0128857. eCollection 2015.
10
Topical microbicides for preventing sexually transmitted infections.用于预防性传播感染的局部杀菌剂。
Cochrane Database Syst Rev. 2021 Mar 13;3(3):CD007961. doi: 10.1002/14651858.CD007961.pub3.

引用本文的文献

1
Counterfactual Groups to Assess Vaccine or Treatment Efficacy in HIV Prevention Trials in High-Risk Populations in Uganda.用于评估乌干达高危人群中HIV预防试验中疫苗或治疗效果的反事实组。
Vaccines (Basel). 2025 Aug 8;13(8):844. doi: 10.3390/vaccines13080844.
2
Associations between intravaginal practices and incidence of sexually transmitted infections and bacterial vaginosis among women enrolled in the dapivirine vaginal ring trial (The Ring Study) in southwestern Uganda: a retrospective secondary analysis.在乌干达西南部参加地蒽诺素阴道环试验（环研究）的女性中，阴道内操作与性传播感染和细菌性阴道病发病率之间的关联：回顾性二次分析。
BMJ Open. 2024 Apr 8;14(4):e079497. doi: 10.1136/bmjopen-2023-079497.
3

本文引用的文献

1
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.性行为风险补偿在 HIV 感染风险个体的暴露前预防研究中的作用。
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):e9-e13. doi: 10.1097/QAI.0000000000001885.
2
Female sex workers experiences of using contraceptive methods: a qualitative study in Kenya.女性性工作者使用避孕方法的经历：肯尼亚的一项定性研究
BMC Womens Health. 2018 Jun 20;18(1):105. doi: 10.1186/s12905-018-0601-5.
3
Contraceptive Preference Among Women at Risk of HIV Acquisition in a Preparatory Screening Study for a Phase III Microbicide Trial in South Western Uganda.
Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study.
参加开放标签扩展研究的女性对 dapivirine 阴道环的疗效和作用的理解。
AIDS Behav. 2023 Jan;27(1):75-81. doi: 10.1007/s10461-022-03745-y. Epub 2022 Jun 7.
在乌干达西南部为 III 期杀微生物剂试验进行预备性筛选研究中，处于艾滋病毒感染风险中的妇女的避孕偏好。
AIDS Behav. 2018 Jul;22(Suppl 1):131-138. doi: 10.1007/s10461-018-2177-3.
4
Pre-Exposure Prophylaxis (PrEP) Use and Condomless Anal Sex: Evidence of Risk Compensation in a Cohort of Young Men Who Have Sex with Men.暴露前预防（PrEP）的使用和无保护肛交：男男性行为者队列中风险补偿的证据。
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):358-364. doi: 10.1097/QAI.0000000000001604.
5
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.双汰芝阴道环预防女性艾滋病的安全性和有效性。
N Engl J Med. 2016 Dec 1;375(22):2133-2143. doi: 10.1056/NEJMoa1602046.
6
Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.多人群中使用口服暴露前预防（PrEP）预防HIV的价值观和偏好：文献系统综述
AIDS Behav. 2017 May;21(5):1325-1335. doi: 10.1007/s10461-016-1627-z.
7
HIV pre-exposure prophylaxis for women.女性 HIV 暴露前预防。
J Virus Erad. 2016 Jul 1;2(3):149-55. doi: 10.1016/S2055-6640(20)30458-1.
8
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.使用含达匹韦林的阴道环预防女性感染HIV-1。
N Engl J Med. 2016 Dec 1;375(22):2121-2132. doi: 10.1056/NEJMoa1506110. Epub 2016 Feb 22.
9
Tenofovir-based preexposure prophylaxis for HIV infection among African women.基于替诺福韦的暴露前预防用于非洲女性的HIV感染
N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.
10
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.在每日口服 HIV 暴露前预防的 iPrEx 试验中没有发现性风险补偿的证据。
PLoS One. 2013 Dec 18;8(12):e81997. doi: 10.1371/journal.pone.0081997. eCollection 2013.